[UPDATE: I am under the impression that Bayer-Schering Pharma sells this product -- like the Levitra® products -- through an arm of Schering Corporation, an affiliate of Schering-Plough -- in some jurisdictions around the world. I am confirming which countries, and whether it is sold under the same sort of an marketing agreement/license as Levitra® (from Bayer-Schering Pharma). Thanks go to a commenter, below for asking after the relationship. Do see the Levitra series of posts, as well.]
After an en banc rehearing petition filed by Schering/Bayer was denied this afternoon, the full panel of U.S. Court of Appeals for the Federal Circuit in Washington, D.C. has effectively let stand the decision of a three member Court of Appeals panel in that Circuit. The upshot of all of this is that Schering's Yasmin birth control pills may now reach the market in an authorized generic form, as marketed in the US and Europe by Teva Pharmaceuticals. Per Bloomberg wire reporting:
. . . .The full panel of U.S. Court of Appeals for the Federal Circuit in Washington declined to revisit an August judgment upholding a lower-court ruling that forced. . . an agreement to let Teva Pharmaceutical Industries Ltd.’s Barr unit begin selling Yasmin under its own label. . . .
The U.S. Court of Appeals for the Federal Circuit, in a 2-1 ruling, said in August that the trial judge was correct to rule that it would have been obvious for scientists to test a smaller particle size because it was well known that drospirenone was acid-sensitive. . . .